TY - JOUR
T1 - Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients
T2 - comprehensive analysis in a single center
AU - Okada, Akira
AU - Ushigome, Hidetaka
AU - Kanamori, Misaki
AU - Morikochi, Aya
AU - Kasai, Hidefumi
AU - Kosaka, Tadashi
AU - Kokuhu, Takatoshi
AU - Nishimura, Asako
AU - Shibata, Nobuhito
AU - Fukushima, Keizo
AU - Yoshimura, Norio
AU - Sugioka, Nobuyuki
N1 - Funding Information:
This study was supported by Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan (AO).
Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose: Cyclosporine A (CyA), a potent immunosuppressive agent used in renal transplantation, has a narrow therapeutic window and a large variability in blood concentrations. This study aimed to develop a population pharmacokinetic (PPK) model of CyA in living-donor renal transplant patients at a single center and identify factors influencing CyA pharmacokinetics (PK). Methods: A total of 660 points (preoperative) and 4785 points (postoperative) of blood concentration data from 98 patients who underwent renal transplantation were used. Pre- and postoperative CyA model structure and PPK parameters were separately estimated with a non-linear mixed-effect model, and subsequently, covariate analysis of postoperative data were comprehensively estimated, including preoperative PK parameters. Results: A two-compartment model with first-order absorption and absorption lag time was selected in this study. Aspartate aminotransferase, body surface area (BSA), pretransplant area under the whole blood concentration–time curve/dose, and postoperative days were identified as the covariates on oral clearance. BSA was selected as a covariate of the distribution volume of the central compartment. In addition, diabetes mellitus was selected as a covariate of the first-order absorption rate. Conclusions: This PPK study used the largest number of blood concentration data among previous reports of living-donor renal transplant patients. Moreover, all patients received the same immunosuppressive regimen in a single center. Therefore, the validity of the selected covariates is reliable with high precision. The developed PPK model and selected covariates provide useful information about factors influencing CyA PK and greatly contributes to the identification of the most suitable dosing regimen for CyA.
AB - Purpose: Cyclosporine A (CyA), a potent immunosuppressive agent used in renal transplantation, has a narrow therapeutic window and a large variability in blood concentrations. This study aimed to develop a population pharmacokinetic (PPK) model of CyA in living-donor renal transplant patients at a single center and identify factors influencing CyA pharmacokinetics (PK). Methods: A total of 660 points (preoperative) and 4785 points (postoperative) of blood concentration data from 98 patients who underwent renal transplantation were used. Pre- and postoperative CyA model structure and PPK parameters were separately estimated with a non-linear mixed-effect model, and subsequently, covariate analysis of postoperative data were comprehensively estimated, including preoperative PK parameters. Results: A two-compartment model with first-order absorption and absorption lag time was selected in this study. Aspartate aminotransferase, body surface area (BSA), pretransplant area under the whole blood concentration–time curve/dose, and postoperative days were identified as the covariates on oral clearance. BSA was selected as a covariate of the distribution volume of the central compartment. In addition, diabetes mellitus was selected as a covariate of the first-order absorption rate. Conclusions: This PPK study used the largest number of blood concentration data among previous reports of living-donor renal transplant patients. Moreover, all patients received the same immunosuppressive regimen in a single center. Therefore, the validity of the selected covariates is reliable with high precision. The developed PPK model and selected covariates provide useful information about factors influencing CyA PK and greatly contributes to the identification of the most suitable dosing regimen for CyA.
KW - Covariate analysis
KW - Cyclosporine
KW - Population pharmacokinetics
KW - Renal transplantation
UR - http://www.scopus.com/inward/record.url?scp=85020532945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020532945&partnerID=8YFLogxK
U2 - 10.1007/s00228-017-2279-2
DO - 10.1007/s00228-017-2279-2
M3 - Article
C2 - 28620753
AN - SCOPUS:85020532945
SN - 0031-6970
VL - 73
SP - 1111
EP - 1119
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 9
ER -